NDA 208143 · Bracco
Varibar Honey
Barium Sulfate · Oral · Radiographic Contrast Agent
Last checked: Nov 20, 2026Latest source record: Mar 10, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Jan 15, 2016
Approved uses
7
Original approval plus efficacy supplements
Registered trials
25
4 Phase 3, 5 recruiting
FAERS reports
353
212 serious, 31 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 15, 2026.
VARIBAR THIN HONEY is indicated for modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. VARIBAR THIN HONEY is a radiopaque contrast agent indicated for use in modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients ( 1 )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 29, 2020 Supplement 11 · Efficacy LabelLetter
- Mar 26, 2018 Supplement 7 · Efficacy LabelLetter
- Jan 23, 2018 Supplement 6 · Efficacy LabelLetter
- Aug 4, 2017 Supplement 5 · Efficacy LabelLetter
- Jul 7, 2017 Supplement 4 · Efficacy LabelLetter
- Mar 1, 2017 Supplement 2 · Efficacy LabelLetter
- Jan 15, 2016 Original approval · Type 7 - Drug Already Marketed without Approved NDA ReviewPediatric Medical ReviewPediatric Medical Review
8 products under this application
- VARIBAR HONEY · BARIUM SULFATE 40% · SUSPENSION, ORAL · Prescription
- TAGITOL V · BARIUM SULFATE 40% · SUSPENSION, ORAL · Prescription
- LIQUID E-Z-PAQUE · BARIUM SULFATE 60% · SUSPENSION, ORAL · Prescription
- READI-CAT 2 · BARIUM SULFATE 2% · SUSPENSION, ORAL · Prescription
- ENTERO VU 24% · BARIUM SULFATE 24% · SUSPENSION, ORAL · Prescription
- VARIBAR THIN HONEY · BARIUM SULFATE 40% · SUSPENSION, ORAL · Prescription
- VARIBAR NECTAR · BARIUM SULFATE 40% · SUSPENSION, ORAL · Prescription
- READI-CAT 2 SMOOTHIE · BARIUM SULFATE 2% · SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Barium" as an intervention, any sponsor and status, largest first.
- Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid.Pivotal-lookingCompleted
Fundación Canaria Rafael Clavijo para la Investigación BiomédicaAcademic, hospital or other
NCT02073552 · 472 participants · Start May 2014 · Primary completion Dec 2015
Drug: Polyethylene glycol 4000; Macrogol 3350 plus ascorbic acid · For: Colonoscopy Preparation
Sites: Santa Cruz de Tenerife, Spain
Mayo ClinicAcademic, hospital or other
NCT05541016 · 455 participants (planned) · Start Mar 20, 2023 · Primary completion Sep 6, 2029
Drug: Cisplatin; Docetaxel · For: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 and 4 more
Sites: Scottsdale, Arizona; Jacksonville, Florida; Rochester, Minnesota
- A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00620035 · 301 participants · Start Mar 2007 · Primary completion Oct 2010
Drug: Radiopaque Etonogestrel Implant · For: Contraception
- Cleansing Options in Out-Patient Setting to Improve Tolerance (COOP SIT) TrialPivotal-lookingRecruiting
Morehouse School of MedicineAcademic, hospital or other
NCT07215000 · 300 participants (planned) · Start Oct 1, 2025 · Primary completion Jan 2027
Drug: Golytely; Sulfave and 1 more · For: Colorectal Cancer Screening; Bowel Cleansing for Colonoscopy
Sites: Atlanta, Georgia
- Cough, Expiratory Training, and Chronic Aspiration After Head and Neck RadiotherapyActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT02662907 · 175 participants · Start Feb 1, 2016 · Primary completion Feb 2, 2027
Drug: Barium · For: Head and Neck Cancer
Sites: Houston, Texas
University of FloridaAcademic, hospital or other
NCT02390089 · 158 participants · Start Apr 2015 · Primary completion Feb 10, 2017
Drug: Capsaicin vapor · For: Parkinson's Disease
Sites: Gainesville, Florida
- Optimisation and Performance of Reduced Preparation CT ColographyPivotal-lookingCompleted
London North West Healthcare NHS TrustAcademic, hospital or other
NCT00212433 · 120 participants · Start Jul 2004
Drug: Tagitol V, Lo So, Readi-Cat 2 · For: Patients With Potential Colorectal Neoplasia
Sites: London, United Kingdom; Oxford, United Kingdom · 3 sites in all
- A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00620464 · 108 participants · Start May 2005 · Primary completion Feb 2009
Drug: Radiopaque Implanon; Implanon (etonogestrel implant) · For: Contraception
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- urticaria27
- diarrhoea26
- pruritus19
- acute kidney injury18
- dyspnoea18
- renal failure18
- no adverse event16
- vomiting16
- chronic kidney disease15
- rash15
- abdominal pain13
- nausea13
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 21 |
| 2009 | 6 |
| 2010 | 10 |
| 2011 | 13 |
| 2012 | 12 |
| 2013 | 17 |
| 2014 | 13 |
| 2015 | 9 |
| 2016 | 20 |
| 2017 | 28 |
| 2018 | 27 |
| 2019 | 27 |
| 2020 | 18 |
| 2021 | 27 |
| 2022 | 32 |
| 2023 | 23 |
| 2024 | 12 |
| 2025 | 17 |
| 2026 | 13 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Chaihu-Shugan-San on functional dyspepsia and gut microbiota: A randomized, double-blind, placebo-controlled trial.
Wang Y, Jia Y, Liu X, et al. · J Ethnopharmacol 2024 · Randomized Controlled Trial
- Influence of Wrap Fixation Technique on the Results of Fundoplication.
Paranyak M, Patel R, Grubnyk V, et al. · Surg Laparosc Endosc Percutan Tech 2021 · Randomized Controlled Trial
- Healthy Volunteers Immediately Adapt to Submental Stimulation During Swallowing.
Safi MF, Martin S, Gray L, et al. · Neuromodulation 2022 · Randomized Controlled Trial
- Effects of bolus rheology on aspiration in patients with Dysphagia.
Leonard RJ, White C, McKenzie S, et al. · J Acad Nutr Diet 2014 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Early topical mitomycin-C prevents stricture formation in children with caustic ingestion.
Sawires H, Aeskander A, El-Sayed M, et al. · J Paediatr Child Health 2024 · Randomized Controlled Trial
- Intrarater and interrater reliability for measurements in videofluoroscopy of swallowing.
Baijens L, Barikroo A, Pilz W · Eur J Radiol 2013 · Meta-Analysis, Systematic Review
Sponsor: Bracco · Also marketed as Tagitol V, Liquid E-Z-Paque, Readi-Cat 2, Entero Vu 24%, Varibar Thin Honey
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.